Kobo Biotech Ltd

Know More
Stock not tradded

4.93-0.19 (-3.71%)

04:01 PM,28th Feb 2024

BSE : 531541


Sector : Health care

ISIN Code : INE881A01015

  • NSE
  • BSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Last Updated: Feb 28 2024 | 04:01 PM IST

Market Cap (₹ Cr)


Turnover (₹ Cr)


Volume (Shares)

Face Value


52-WK High


52-WK High Date

Invalid date

52-WK Low


52-WK Low Date

Invalid date

All Time High


All Time High Date

Invalid date

All Time Low


All Time Low Date

Invalid date

Kobo Biotech Ltd

Kobo Biotech Ltd.(Formerly known Avon Lifesciences Ltd) was established as a Public Limited Company on August 3 1992. Effective 19th October 2020 the Company's name was changed to Kobo Biotech Limited from erstwhile Avon Lifesciences Limited. The Company is a customer-centric manufacturer of active pharmaceutical ingredients (API).Promoted by P R Agarwal Rajesh Agarwal and G S Sidhu the Company manufacture diketene and its derivatives Monomethyl Acetoncetamide(MMA) and Methyl Acetoacetate(MAA). The company's 1200 tpa Diketene manufacturing faciltiy located at Sadashivpet in Andhrapradesh and the products of it were used in pigments pharmaceuticals and pesticides. The company has a tripartite technical knowhow agreement with Shanghai Machinery & Equipment Import and Export Corporation (SMEC) representative of Shanghai Peng Pu Chemical Works (SPCW) and Xytel Technologies Partnership (XTP) US. XTP shall be the technical supervisor for the transfer of technology while SMEC shall supply the technical knowhow.The company has bagged the award for the Best New Product manufactured in the State of Andhra Pradesh as awarded by the Federation of Andhra Pradesh Chamber of Commerce and Industry and also certified as an ISO 9002 company by American Quality Asseassors accredited with ANSI-RAB for the manufacturing and marketing MMAA MMAE DEA EEAA and Aralydes.The company had developed technology for recovery of Diketene from sludge. The company has also diversified into Bio-Technology where the value addition is high. To part finance its biotech project the company has made a preferential issue of 1800000 Equity shares at Rs. 38.75 each aggregating to Rs. 697.50 lacs and issued 400000 warrants convertible into 400000 equity shares during the year 1999-2000.The Bio-Technology Plant is located at SolapurMaharashtra for manufacture of Ephedrine and Pseudo-Ephedrine with an installed capacity of 150 MT p.a. The plant has commenced operations during April 2001. The biotech division produces Pharmaceutical intermediates i.e Pseudoephedrine and ephedrine. The company has signed two longterm export contracts to supply fixed quantities of Pseudoephedrine and is in talks with a few more MNC's for long term contracts during the year 2001-02. The company's bio-tech division is pursuing USFD approval which will enable it to enter into regulated markets.The company is all set to introduce two high value added intermediates in its Diketene Division.The company has already completed trial production for these two pharmaceutical products and is ready for commercial launch.The company is expected an additional turnover of Rs.12 crores from these products from the year 2005-06.During the year 2004-05 the Company increased its production capacity in Biotech Division. Further the company has increased the storage capacity of molasses from 2000 tons to 6000 tons.The Company in 2006-07 had received USFDA approval for its facilities at Biotech Division at Solapur Maharashtra for manufacture of Psuedoephedrine.Pursuant to the preferential issue of 9809100 equity shares [43.60% of the total paid-up equity share capital] of the Company to Arch Pharmalabs Limited in November 2007 the SEBI [Substantial Acquisition of Shares and Takeovers] Regulations 1997 were attracted and accordingly Arch Pharmalabs Limited a Mumbai based Company engaged in business of manufacturing Pharmaceutical Intermediates and Active Pharmaceutical Ingredients was obligated to acquire upto 4500000 equity shares of Rs.10/- each representing 20% of the share capital of the Company.Further on receipt of SEBI approval for the Open Offer vide SEBI letter dated 11th November 2008 the Open Offer continued from 3rd December 2008 till 22nd December 2008. Pursuant to the closure of the Offer 4500000 equity shares were accepted in the Open Offer at an offer price of Rs. 21.85 for each equity share and subsequently transferred to Arch Pharmalabs Limited on 31 January 2009. Post-transfer the shareholding of Arch Pharmalabs Limited in the Company was 14309100 equity shares comprising 63.60% of the total equity capital of the Company. Pursuant to Arch Pharmalabs Limited acquiring a majority stake of 63.60% in the Company the Company became a subsidiary of Arch Pharmalabs Limited.Regal Pharma PTE Ltd. was formed as wholly owned subsidiary company in Singapore on May 15 2010.

Kobo Biotech Ltd - Key Fundamentals

Market Cap (₹ Cr)


EPS - TTM (₹) [S]


P/E Ratio (X) [S]


Face Value (₹) 10
Latest Dividend (%)10.00
Latest Dividend Date 21 Sep 2012
Dividend Yield (%) -
Book Value Share (₹) [S]-54.74
P/B Ratio (₹) [S]-0.09
[*C] Consolidated [*S] Standalone

Funds Owing this Stock

Scheme Name Amount Invested ( ₹ Cr ) No Of Shares Net Asset (%)

Research Reports

Date BrokerActionPrices(Rs)Report
Data Not Found

Stock Strength

Today's Low/High



Week Low/High



Month Low/High



Year Low/High



All time Low/High



Share Price Returns

1 Week-2.95%%-0.44-0.47%
1 Month25.77%%2.272.80%
3 Month58.01%%9.2610.36%
6 Month63.79%%11.2413.70%
1 Year106.28%%22.6326.86%
3 Year16.00%%47.2651.08%

Company Info

Company Information

Chairman (Non-Executive) : Ajit Kamath

Non-Exec & Non-Independent Dir : Rajendra Kaimal

Company Sec. & Compli. Officer : Jignesh Patel

Non-Exec. & Independent Dir. : Sunil Pitroda

Non-Exec. & Independent Dir. : Abhishek Buddhadev

Non-Exec. & Independent Dir. : Urja Shah

Registered Office: Ground Flr D No 8-2-684/J/8/A, Bhavani Nagar Banjara Hills,Hyderabad,Telangana-500034 Ph: